🚨 #IUCS Clinical Poll | #ESMO26
70M with cT3N0M0 MIBC, cisplatin-ineligible, planned for radical cystectomy.
Ahead of VOLGA (LBA2), which factor will matter most when interpreting the results?
🗳️ Vote now! Let's discuss after the presentation.
@gbanna74 @ravikanesvaran @nataliagandur @neerajaiims @Sebastiano_Buti @CinziaConted @dralishadamani @amg120395 @PGrivasMDPhD @koshkin85 @MicheleMaffezz @ParamMariappan @dmukherji @VanitaNoronha @montypa @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @DrYukselUrun @yekeduz_emre @AgrawalTrush
#IUCS26 #ESMO26 #BladderCancer
55 views · 1 like · 1 repost · 0 replies
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: International Urology Cancer Summit · x.com